

FAX FORM TO: 1.866.233.8317

PHONE: 1.855.492.0817

EMAIL: contact@bluegrass-rx.com

Complete the following or include demographic sheet.

1. PATIENT INFORMATION		2. PRESCRIBER INFORMATION	
Name:		Name:	
Address:		DEA #:	NPI #: State Lic. #:
City, State, ZIP:		Group or Hospital:	
Primary Phone: - -	DOB: / /	Address:	
Alternate Phone: - -	Gender:	City, State, Zip:	
Email:		Phone: - -	Fax: - -
Primary Language:	Last Four of SSN:	Contact Person: Phone: - -	

3. INSURANCE INFORMATION		<i>Fax copy of prescription and insurance cards with this form, if available (front and back)</i>	
Primary Insurance Company Name:		Secondary Insurance Company Name:	
Primary Cardholder Name:		Secondary Cardholder Name:	
Relationship: <input type="radio"/> Self <input type="radio"/> Spouse/Partner <input type="radio"/> Child/Dependent		Relationship: <input type="radio"/> Self <input type="radio"/> Spouse/Partner <input type="radio"/> Child/Dependent	
Phone: - -	Member ID: Group #:	Phone: - -	Member ID: Group #:

4. DIAGNOSIS AND CLINICAL INFORMATION	
Needs by Date: / /	Ship to: <input type="radio"/> Patient <input type="radio"/> Office <input type="radio"/> Other:
Date of Diagnosis: / /	Last Visit: / / Next Visit: / /
<input type="radio"/> E22.0 Acromegaly and pituitary gigantism	Height (in/cm): Weight (lb/kg): IGF-1 levels: GH levels:
<input type="radio"/> Other:	Has patient previously been on medication for acromegaly? <input type="radio"/> Yes <input type="radio"/> No
Allergies:	If yes, start date and product:
Current Medications:	Does this patient have an active pituitary tumor or history of one? <input type="radio"/> Active <input type="radio"/> History <input type="radio"/> No
Has patient received injection training? <input type="radio"/> Yes <input type="radio"/> No	If history, how long has the tumor been absent?
<input type="radio"/> Patient is interested in patient support programs.	Is the patient a candidate for radiation or surgery? <input type="radio"/> Yes <input type="radio"/> No
	Has the patient had an inadequate response to radiation or surgery? <input type="radio"/> Yes <input type="radio"/> No

5. PRESCRIPTION INFORMATION				
Medication	Dose/Strength	Directions	Quantity	Refills
<input type="radio"/> Sandostatin Injection® Ampules	<input type="radio"/> 50 mcg/ml <input type="radio"/> 100 mcg/ml <input type="radio"/> 500 mcg/ml	<input type="radio"/> Administer ____ mcg subcutaneously three times daily. <input type="radio"/> Other:		
<input type="radio"/> Sandostatin Injection® MDV	<input type="radio"/> 200 mcg/ml (5 ml) <input type="radio"/> 200 mcg/ml (5 ml)	<input type="radio"/> Administer ____ mcg subcutaneously three times daily. <input type="radio"/> Other:		
<input type="radio"/> Sandostatin LAR® Depot	<input type="radio"/> 10 mg vial kit <input type="radio"/> 20 mg vial kit <input type="radio"/> 30 mg vial kit	<input type="radio"/> Administer ____ mcg subcutaneously three times daily. <input type="radio"/> Other:	<input type="radio"/> 4-week supply <input type="radio"/> 12-week supply <input type="radio"/> Other:	
<input type="radio"/> Somatuline® Depot	<input type="radio"/> 60 mg prefilled syringes <input type="radio"/> 90 mg prefilled syringes <input type="radio"/> 120 mg prefilled syringes	<input type="radio"/> Inject 90 mg (1 syringe) SQ every 4 weeks. <input type="radio"/> Other: Inject _____ mg (1 syringe) SQ every 4 weeks.	<input type="radio"/> 4-week supply <input type="radio"/> 12-week supply <input type="radio"/> Other:	
<input type="radio"/> Somavert® (LD)'	(LD)' This is a limited distribution drug that requires additional handling. Please call (1.855.492.0817) for more information.			
<input type="radio"/>				

Ancillary supplies and kits will be provided as needed for administration.

6. PRESCRIBER SIGNATURE	
X _____ / /	X _____ / /
DISPENSE AS WRITTEN	PRODUCT SUBSTITUTION PERMITTED
DATE	DATE

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address or telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.